Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2002-08-01
2009-12-08
Angell, J. E (Department: 1635)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
Reexamination Certificate
active
07629153
ABSTRACT:
The present invention provides HIV-derived lentivectors which are multiply modified to create highly safe, efficient, and potent vectors for expressing transgenes for gene therapy. The lentiviral vectors comprise various combinations of an inactive central polypurine tract, a stuffer sequence, which may encode drug susceptibility genes, and a mutated hairpin in the 5′ leader sequence that substantially abolishes replication. These elements are provided in conjunction with other features of lentiviral vectors, such as a self-inactivating configuration for biosafety and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments for inherited and acquired disorders, gene-therapies for cancers and other disease, the creation of industrial and experimental production systems utilizing transformed cells, as well as for the study of basic cellular and genetic processes.
REFERENCES:
patent: 4682195 (1987-07-01), Yilmaz
patent: 4683202 (1987-07-01), Mullis
patent: 5015573 (1991-05-01), Yarranton et al.
patent: 5019384 (1991-05-01), Gefter et al.
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5645897 (1997-07-01), Andra
patent: 5686279 (1997-11-01), Finer et al.
patent: 5705629 (1998-01-01), Bhongle
patent: 5846225 (1998-12-01), Rosengart et al.
patent: 5846233 (1998-12-01), Lilley et al.
patent: 5885570 (1999-03-01), Isobe et al.
patent: 5912411 (1999-06-01), Bujard et al.
patent: 5925565 (1999-07-01), Berlioz et al.
patent: 5928906 (1999-07-01), Koster et al.
patent: 5935819 (1999-08-01), Eichner et al.
patent: 5981830 (1999-11-01), Wu et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6017758 (2000-01-01), Haselton, III et al.
patent: 6031517 (2000-02-01), Van Nes
patent: 6084063 (2000-07-01), Vonakis et al.
patent: 6096538 (2000-08-01), Kingsman et al.
patent: 6136597 (2000-10-01), Hope et al.
patent: 6165782 (2000-12-01), Naldini et al.
patent: 6168916 (2001-01-01), Kingsman et al.
patent: 6207455 (2001-03-01), Chang
patent: 6218181 (2001-04-01), Verma et al.
patent: 6218186 (2001-04-01), Choi et al.
patent: 6235522 (2001-05-01), Kingsman et al.
patent: 6242258 (2001-06-01), Haselton, III et al.
patent: 6271359 (2001-08-01), Norris et al.
patent: 6277633 (2001-08-01), Olsen
patent: 6312682 (2001-11-01), Kingsman et al.
patent: 6312683 (2001-11-01), Kingsman et al.
patent: 6340741 (2002-01-01), Mermod et al.
patent: 6410313 (2002-06-01), Kasahara et al.
patent: 6428953 (2002-08-01), Naldini et al.
patent: 6440730 (2002-08-01), Von Laer et al.
patent: 6444871 (2002-09-01), Yao
patent: 6485965 (2002-11-01), Klatzmann et al.
patent: 6531123 (2003-03-01), Chang
patent: 6682907 (2004-01-01), Charneau et al.
patent: 6852703 (2005-02-01), Kingsman et al.
patent: 7202079 (2007-04-01), Luo et al.
patent: 2001/0009772 (2001-07-01), Verma et al.
patent: 2002/0034393 (2002-03-01), Mitrophanous et al.
patent: 2002/0034502 (2002-03-01), Kingsman et al.
patent: 2002/0048805 (2002-04-01), Johnston et al.
patent: 2002/0123471 (2002-09-01), Uberla
patent: 2002/0160393 (2002-10-01), Symonds et al.
patent: 2003/0082789 (2003-05-01), Trono et al.
patent: 2003/0119770 (2003-06-01), Lai et al.
patent: 2005/0148078 (2005-07-01), Luo et al.
patent: 0266032 (1988-05-01), None
patent: 0476953 (1992-03-01), None
patent: 1229134 (2002-08-01), None
patent: 1371727 (2003-12-01), None
patent: 1222300 (2006-05-01), None
patent: 1238092 (2007-01-01), None
patent: WO 99/04026 (1999-01-01), None
patent: WO 99/51754 (1999-10-01), None
patent: WO 00/12737 (2000-03-01), None
patent: WO 00/15819 (2000-03-01), None
patent: WO 00/55335 (2000-09-01), None
patent: WO 00/66758 (2000-11-01), None
patent: WO 01/27300 (2001-04-01), None
patent: WO 01/27304 (2001-04-01), None
patent: WO 0127304 (2001-04-01), None
patent: WO 01/34843 (2001-05-01), None
patent: WO 01/44458 (2001-06-01), None
patent: WO 01/44481 (2001-06-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 01/92506 (2001-12-01), None
patent: WO 02/066638 (2002-08-01), None
patent: WO 02/087341 (2002-11-01), None
patent: WO 03/022052 (2003-03-01), None
patent: WO 03/072788 (2003-09-01), None
Akkina et al., “High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G,”J. Virol., 70:2581-2585, 1996.
Almendro et al., “Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization,”J. Immunol., 157(12):5411-5421, 1996.
An et al., “Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells,”J. Virol., 74:1286-1295,.2000.
Angel et al., “12-0-tetradecanoyl-phorbol-13-acetate Induction of the Human Collagenase Gene is Mediated by an Inducible Enhancer Element Located in the 5' Flanking Region,”Mol. Cell. Biol., 7:2256-2266, 1987.
Angel et al., “Phorbol Ester-Inducible Genes Contain a Common cis Element Recognized by a TPA-Modulated Trans-acting Factor,”Cell, 49:729-739, 1987.
Arrighi et al., “Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(−)CD14(−) and CD34(−)CD14(+) dendritic cell precursor,”Blood, 93:2244-2252, 1999.
Atchison and Perry, “Tandem Kappa Immunoglobulin Promoters are Equally Active in the Presence of the Kappa Enhancer: Implications for Model of Enhancer Function,”Cell, 46:253-262, 1986.
Atchison and Perry, “The Role of the κ Enhancer and its Binding Factor NF-κB in the Developmental Regulation of κ Gene Transcription,”Cell, 48:121-128, 1987.
Banerji et al., “A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy-chain genes,”Cell, 35:729-740, 1983.
Banerji et al., “Expression of a Beta-Globin Gene is Enhanced by Remote SV40 DNA Sequences,”Cell, 27:299-308, 1981.
Berkhout et al., “Tat Trans-activates the Human Immunodeficiency Virus Through a Nascent RNA Target,”Cell, 59:273-282, 1989.
Bhatia et al., “Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture,”J. Exp. Med., 186:619-624, 1997.
Blanar et al., “A gamma-interferon-induced factor that binds the interferon response sequence of the MHC class I gene, H-2Kb,”EMBO J., 8:1139-1144, 1989.
Blömer et al., “Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector,”J. Virol., 71:6641-6649, 1997.
Bodine and Ley, “An enhancer element lies 3' to the human a γ globin gene,”EMBO J., 6:2997-3004, 1987.
Boshart et al., “A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus,”Cell, 41:521-530, 1985.
Bösze et al., “A transcriptional enhancer with specificity for erythroid cells is located in the long terminal repeat of the friend murine leukemia virus,”EMBO J., 5:1615-1623, 1986.
Braddock et al., “HIV-I Tat activates presynthesized RNA in the nucleus,”Cell, 58:269-279, 1989.
Bray et al., “A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent,”Proc. Natl. Acad. Sci. USA, 91:1256-1260, 1994.
Brown et al., “Efficient polyadenylation within the human immunodeficiency virus type 1 long terminal repeat requires flanking U3-specific sequences,”J. Virol., 65:3340-3343, 1991.
Bulla and Siddiqui, “The hepatitis B virus enhancer modulates transcript
Trono Didier
Zufferey Romain N.
Angell J. E
Fulbright & Jaworski L.L.P.
Research Development Foundation
LandOfFree
Methods and compositions relating to improved lentiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to improved lentiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to improved lentiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058070